是不是这个原因？但其他医疗股木有怎么长啊。 STRONG GROWTH IN MEDICAL TRAVELLERS REPORTED
Channel NewsAsia reported last Friday that private hospital operators have experienced a double-digit jump in foreign patient arrivals in Singapore over the past year1.
We believe this is underpinned by growing affluence in the region and Singapore’s acclaimed status as Asia’s medical hub, given its ability to offer sophisticated medical specialties and procedures of a high quality. This is supported by state-of-the-art infrastructure and a highly-skilled medical workforce, thus enabling certain private hospital operators to command a higher premium for their services.
Raffles Medical Group (RMG) was reported to have experienced a 26% YoY rise in its foreign patient arrivals. We like RMG for its defensive earnings and strong track record. In our view, this offers investors a strong investment proposition, especially given the ongoing turmoil in the global economy. Reiterate our BUY rating and S$2.58 fair value estimate on RMG. The group trades at 21.8x FY12F and 18.9x FY13F PER, respectively, versus its peers’ average FY-1 and FY-2 PER of 29.2x and 22.8x, respectively.
We also maintain our OVERWEIGHT rating on the broader healthcare sector.
窦枝
是不是这个原因？但其他医疗股木有怎么长啊。
STRONG GROWTH IN MEDICAL TRAVELLERS REPORTED
Channel NewsAsia reported last Friday that private hospital operators have experienced a double-digit jump in foreign patient arrivals in Singapore over the past year1.
We believe this is underpinned by growing affluence in the region and Singapore’s acclaimed status as Asia’s medical hub, given its ability to offer sophisticated medical specialties and procedures of a high quality. This is supported by state-of-the-art infrastructure and a highly-skilled medical workforce, thus enabling certain private hospital operators to command a higher premium for their services.
Raffles Medical Group (RMG) was reported to have experienced a 26% YoY rise in its foreign patient arrivals. We like RMG for its defensive earnings and strong track record. In our view, this offers investors a strong investment proposition, especially given the ongoing turmoil in the global economy. Reiterate our BUY rating and S$2.58 fair value estimate on RMG. The group trades at 21.8x FY12F and 18.9x FY13F PER, respectively, versus its peers’ average FY-1 and FY-2 PER of 29.2x and 22.8x, respectively.
We also maintain our OVERWEIGHT rating on the broader healthcare sector.